Oral glucagon-like peptide-1 receptor agonists - Crinetics Pharmaceuticals
Latest Information Update: 10 May 2024
At a glance
- Originator Crinetics Pharmaceuticals
- Class Antihyperglycaemics; Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Diabetes mellitus; Obesity
Most Recent Events
- 25 Apr 2024 Early research in Diabetes mellitus in USA (PO), prior to April 2024 (Crinetics Pharmaceuticals pipeline, April 2024)
- 25 Apr 2024 Early research in Obesity in USA (PO), prior to April 2024 (Crinetics Pharmaceuticals pipeline, April 2024)
- 25 Apr 2024 Crinetics Pharmaceuticals intends to announce lead candidate in oral glucagon-like peptide-1 receptor agonists in 2025